Amedisys, Inc. (NASDAQ:AMED) Shares Sold by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership lowered its position in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 63.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,976 shares of the health services provider's stock after selling 8,594 shares during the quarter. Arrowstreet Capital Limited Partnership's holdings in Amedisys were worth $452,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AMED. Blue Trust Inc. grew its stake in shares of Amedisys by 55.1% in the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock valued at $34,000 after buying an additional 124 shares during the period. HBW Advisory Services LLC acquired a new position in Amedisys in the fourth quarter valued at approximately $38,000. Versant Capital Management Inc grew its position in Amedisys by 68.5% in the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider's stock worth $41,000 after acquiring an additional 183 shares during the period. Vestcor Inc acquired a new stake in Amedisys during the fourth quarter worth $73,000. Finally, Venturi Wealth Management LLC raised its position in Amedisys by 397.4% in the fourth quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider's stock valued at $89,000 after purchasing an additional 779 shares during the period. 94.36% of the stock is currently owned by institutional investors and hedge funds.

Amedisys Trading Down 0.2 %

AMED traded down $0.15 during mid-day trading on Friday, hitting $91.76. 133,860 shares of the stock were exchanged, compared to its average volume of 400,335. The firm's fifty day moving average is $92.14 and its two-hundred day moving average is $91.91. Amedisys, Inc. has a 1-year low of $82.15 and a 1-year high of $98.95. The company has a market cap of $3.01 billion, a PE ratio of 36.41, a PEG ratio of 1.78 and a beta of 0.89. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMED - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.05 by ($0.09). The business had revenue of $598.05 million for the quarter, compared to analyst estimates of $602.38 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. Equities analysts forecast that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AMED has been the subject of a number of research analyst reports. Stephens reiterated an "equal weight" rating and set a $101.00 price target on shares of Amedisys in a report on Tuesday, March 4th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $100.00 target price on shares of Amedisys in a research note on Wednesday. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $100.75.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.